Candida prophylaxis and therapy in the ICU.

Area of Science:

• Critical care medicine
• Infectious diseases
• Mycology

Background:

• Invasive candidiasis incidence is rising in critically ill patients, leading to high morbidity and mortality.
• Candida species, including Candida albicans and non-albicans Candida like Candida glabrata, are frequently identified in ICU patients.
• Current diagnostic methods, primarily blood cultures, have low sensitivity for detecting Candida.

Purpose of the Study:

• To review the current landscape of invasive candidiasis in critically ill patients.
• To discuss the evolving role and strategies of antifungal therapy, including prophylaxis, preemptive, and empirical approaches.
• To highlight the need for further prospective trials to refine treatment guidelines.

Main Methods:

• Review of current literature and clinical guidelines regarding invasive candidiasis and antifungal therapy.
• Analysis of incidence trends, diagnostic challenges, and therapeutic strategies.
• Synthesis of information on azole derivatives, echinocandins, and polyenes.

Main Results:

• Candida is present in up to 17% of ICU patients, with candidemia in approximately 1%.
• Candida albicans remains common, but non-albicans species are increasing.
• Antifungal therapy is increasingly used prophylactically, preemptively, and empirically.

Conclusions:

• Optimizing antifungal therapy for invasive candidiasis in critically ill patients requires better patient stratification.
• Current guidelines assist in selecting antifungals like azoles, echinocandins, or polyenes.
• Prospective trials are essential to establish definitive evidence-based treatment protocols for confirmed or at-risk invasive Candida infections.